By
John F. Reitan, PharmD
Chairman, RJM Group, LLC, Crown Point, Indiana
Alex T. Makris, MD, CMD
Infectious Disease Consultant and Corporate Medical Director
Seniors Management North, Marlton, New Jersey
Kathleen Ryan Fletcher, RN, MSN, GNP-BC, FAAN
Assistant Professor of Nursing and Director of Senior Services
University of Virginia Health System, Charlottesville, Virginia
Faculty Disclosure
Kathleen Ryan Fletcher, RN, MSN, GNP-BC, FAAN, discloses that she is or has been a member of advisory boards and speakers bureaus for Forest Pharmaceuticals, Inc. and Pfizer Inc.
Alex T. Makris, MD, CMD, has no actual or potential conflicts of interest in relation to this program
John F. Reitan, PharmD discloses that he is or has been a member of speakers bureaus for Ortho-McNeil and Pfizer Inc.
Goals and Objectives
At the end of this lesson, the reader should be able to:
- recognize the threat, presentation, and risk factors for HA-MRSA and CA-MRSA in the LTC setting
- familiarize themselves with the economic burden of managing MRSA in LTC facilities
- implement a team approach to preventing and managing MRSA infections
- evaluate the efficacy and safety of anti-MRSA agents for empiric and directed therapy in HA-MRSA and CA-MRSA
Target Audience
Pharmacists
|
Monograph